PERSPECTA

News from every angle

← Back to headlines

ProKidney Builds Bull Case Around Rilparencel’s Accelerated Approval Path

ProKidney (PROK) is strengthening its investment case by pursuing an accelerated approval pathway for its drug, Rilparencel.

17 Jun, 15:16 — 17 Jun, 15:16
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual37d ago

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

Read full article →

Related Stories

Pangasinan Fisherfolk Receive BFAR Livelihood Aid

just now

Oriental Mindoro Power Cooperative Defends High Rates Amid Probe

just now

Senator Lacson Uncovers More Evidence in Taguig Projects Investigation

just now

Significant Spike Expected in Diesel and Gasoline Prices

just now